Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin
- PMID: 9495304
- DOI: 10.1161/01.cir.97.7.681
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin
Abstract
Background: The presence of residual mural thrombus may predispose to recurrent thrombotic events in acute coronary syndromes. The purpose of this study was to evaluate the effects of antithrombotic and antiplatelet agents on a preformed, fresh mural thrombus during growth of thrombus.
Methods and results: A fresh mural thrombus was formed by perfusing severely injured arterial wall with porcine blood for 5 minutes at a shear rate of 1690 s(-1). Thrombus formation was measured by morphometric analysis (mm2/mm). The average size of a mural thrombus formed in 5 minutes was 0.14+/-0.03 mm2/mm. Progression of thrombus growth within 10 minutes triggered by the preformed thrombus was evaluated in pigs treated with r-hirudin (1 mg/kg per hour i.v.) as a probe for thrombin, high-dose heparin (250 IU/kg per hour i.v.), moderate-dose heparin (100 IU/kg per hour), moderate-dose heparin (100 IU/kg per hour) plus aspirin, aspirin alone (5 mg/kg i.v.), and placebo. Hirudin was associated with a significant decrease (48%) of mural thrombus area and significantly reduced growth of thrombus (0.07+/-0.01), even compared with the highest dose of heparin (0.15+/-0.03), although at lower levels of anticoagulation. Inhibition of growth of thrombus with heparin was dose dependent, showing an inverse correlation of thrombus area with mean plasma heparin concentrations (r=.77, P=.0001). Thrombus size was unchanged by aspirin (0.29+/-0.07) compared with controls (0.28+/-0.07).
Conclusions: Direct inhibition of thrombin activity with r-hirudin completely inhibits growth of thrombus, causes dissolution of a preexisting mural thrombus, and is more effective at lower levels of anticoagulation than the highest dose of heparin at shear rates typical of a moderate coronary stenosis.
Similar articles
-
Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy.Circulation. 1994 Nov;90(5):2432-8. doi: 10.1161/01.cir.90.5.2432. Circulation. 1994. PMID: 7955200
-
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.Thromb Haemost. 1997 Oct;78(4):1278-85. Thromb Haemost. 1997. PMID: 9364998
-
Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.Circulation. 1996 Feb 15;93(4):792-9. doi: 10.1161/01.cir.93.4.792. Circulation. 1996. PMID: 8641009
-
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.Circulation. 1992 Dec;86(6 Suppl):III100-10. Circulation. 1992. PMID: 1424043 Review.
-
Direct thrombin inhibitors in cardiac disease.Cardiovasc Toxicol. 2003;3(1):13-25. doi: 10.1385/ct:3:1:13. Cardiovasc Toxicol. 2003. PMID: 12668887 Review.
Cited by
-
The role of aspirin resistance in the treatment of acute coronary syndromes.Clin Cardiol. 2008 Jan;31(1):11-7. doi: 10.1002/clc.20157. Clin Cardiol. 2008. PMID: 17803242 Free PMC article. Review.
-
DLBS1033, a protein extract from Lumbricus rubellus, possesses antithrombotic and thrombolytic activities.J Biomed Biotechnol. 2011;2011:519652. doi: 10.1155/2011/519652. Epub 2011 Mar 3. J Biomed Biotechnol. 2011. PMID: 21403877 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical